Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0027 Transporter Info | ||||
| Gene Name | SLC22A12 | ||||
| Protein Name | Urate anion exchanger 1 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs11231825 | ||||
| Site of GPD | chr11:64592802 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | T>C | ||||
| Minor Allele Frequency | C=0.3860/1933 (Global) | ||||
| Genotype TT | Click to Show/Hide the Full List of Affected Drugs: 12 Drugs in Total | ||||
| Cytarabine | Drug Info | Acute Myeloid Leukemia | Correlated with the increased likelihood of fever in patients (compare with genotypes CC + CT) | [ 1] | |
| Fludarabine | Drug Info | Acute Myeloid Leukemia | Correlated with the increased likelihood of fever in patients (compare with genotypes CC + CT) | [ 1] | |
| Gemtuzumab ozogamicin | Drug Info | Acute Myeloid Leukemia | Correlated with the increased likelihood of fever in patients (compare with genotypes CC + CT) | [ 1] | |
| Idarubicin | Drug Info | Acute Myeloid Leukemia | Correlated with the increased likelihood of fever in patients (compare with genotypes CC + CT) | [ 1] | |
| Cytarabine | N.A. | Fever | Genotype TT is associated with increased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes CC + CT. | [ 1] | |
| Fludarabine | N.A. | Fever | Genotype TT is associated with increased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes CC + CT. | [ 1] | |
| Gemtuzumab Ozogamicin | N.A. | Fever | Genotype TT is associated with increased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes CC + CT. | [ 1] | |
| Idarubicin | N.A. | Fever | Genotype TT is associated with increased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes CC + CT. | [ 1] | |
| Cytarabine | N.A. | Leukemia, Myeloid, Acute | Genotype TT is associated with increased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes CC + CT. | [ 1] | |
| Fludarabine | N.A. | Leukemia, Myeloid, Acute | Genotype TT is associated with increased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes CC + CT. | [ 1] | |
| Gemtuzumab Ozogamicin | N.A. | Leukemia, Myeloid, Acute | Genotype TT is associated with increased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes CC + CT. | [ 1] | |
| Idarubicin | N.A. | Leukemia, Myeloid, Acute | Genotype TT is associated with increased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotypes CC + CT. | [ 1] | |
| Genotype CC | Click to Show/Hide the Full List of Affected Drugs: 4 Drugs in Total | ||||
| Cytarabine | N.A. | Leukemia, Myeloid, Acute | Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin. | [ 1] | |
| Fludarabine | N.A. | Leukemia, Myeloid, Acute | Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin. | [ 1] | |
| Gemtuzumab Ozogamicin | N.A. | Leukemia, Myeloid, Acute | Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin. | [ 1] | |
| Idarubicin | N.A. | Leukemia, Myeloid, Acute | Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin. | [ 1] | |
| Genotype CT | Click to Show/Hide the Full List of Affected Drugs: 4 Drugs in Total | ||||
| Cytarabine | N.A. | Leukemia, Myeloid, Acute | Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin. | [ 1] | |
| Fludarabine | N.A. | Leukemia, Myeloid, Acute | Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin. | [ 1] | |
| Gemtuzumab Ozogamicin | N.A. | Leukemia, Myeloid, Acute | Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin. | [ 1] | |
| Idarubicin | N.A. | Leukemia, Myeloid, Acute | Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin. | [ 1] | |
| Genetic Polymorphism | rs3825018 | ||||
| Site of GPD | chr11:64591337 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>A | ||||
| Minor Allele Frequency | G=0.6160/1219 (Global) | ||||
| Allele G | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Allopurinol | N.A. | Drug Toxicity | Allele G is not associated with dose of allopurinol in people with Gout as compared to allele A. | [ 2] | |
| Genetic Polymorphism | rs505802 | ||||
| Site of GPD | chr11:64589600 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | T>A / T>C | ||||
| Minor Allele Frequency | T=0.4280/847 (Global) | ||||
| Allele T | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Allopurinol | N.A. | Drug Toxicity | Allele T is associated with increased dose of allopurinol in people with Gout as compared to allele C. | [ 3] | |
| Genetic Polymorphism | rs1529909 | ||||
| Site of GPD | chr11:64598471 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | T>C | ||||
| Minor Allele Frequency | T=0.6120/1211 (Global) | ||||
| Genotypes CC + CT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Losartan | N.A. | Drug Toxicity | Genotypes CC + CT is associated with decreased response to losartan in people with Hypertension and Hyperuricemia as compared to genotype TT. | [ 4] | |
| Genetic Polymorphism | rs3825016 | ||||
| Site of GPD | chr11:64591814 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>T | ||||
| Minor Allele Frequency | C=0.6140/1215 (Global) | ||||
| Genotypes CT + TT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Losartan | N.A. | Drug Toxicity | Genotypes CT + TT is associated with decreased response to losartan in people with Hypertension and Hyperuricemia as compared to genotype CC. | [ 4] | |
| References | |||||
| 1 | Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. Pharmacogenomics J. 2013 Aug;13(4):335-41. | ||||
| 2 | The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool. Br J Clin Pharmacol. 2018 May;84(5):937-943. | ||||
| 3 | Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia. Br J Clin Pharmacol. 2023 Oct;89(10):2964-2976. | ||||
| 4 | URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia. Pharmacogenomics. 2015 Jul;16(8):855-63. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.